Drake Center has signed an agreement with Helsinki-based medical device company
Nexstim Oy to study the benefits of using Navigated Brain Stimulation (NBS) in the diagnosis, monitoring and treatment of patients following a stroke.
According to
UC HealthNews, Nexstim's device stimulates precise areas of the human cortex of the brain while simultaneously measuring the effect of stimuli on the central nervous system and the preipheral nerves responsible for movement.
Although the NBS device has been used for research in Europe and Asia for five years, it has yet to obtain
FDA approval.
Drake Center is only the third research lab in the United States to have the device, and the first inpatient rehabilitation hospital to use it for clinical research.
Read the full article
here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.